Products in development

Fol­low­ing the acqui­si­tion of Icon Genet­ics by the Den­ka Group, Japan, the Den­ka Group is com­mit­ted to devel­op­ing norovirus vac­cine and oth­er vac­cine can­di­dates in col­lab­o­ra­tion with Icon Genet­ics, using the mag­nI­CON® pro­duc­tion tech­nol­o­gy as a replace­ment for tra­di­tion­al man­u­fac­tur­ing meth­ods. Fur­ther­more, the mag­nI­CON® pro­duc­tion plat­form will be applied to improve man­u­fac­tur­ing of recom­bi­nant anti­bod­ies, anti­gens and oth­er pro­teins to be used for diag­nos­tic reagents pro­duced by the Den­ka Group.
Togeth­er with nation­al and inter­na­tion­al cus­tomers and part­ners we devel­op, on con­trac­tu­al basis, a diverse port­fo­lio of recom­bi­nant pro­teins for phar­ma­ceu­ti­cal and diag­nos­tic use. These include virus-like par­ti­cles, anti­bod­ies, viral and bac­te­r­i­al anti­gens, acces­so­ry pro­tein com­po­nents for diag­nos­tic reagents and more.